Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Soros moves on

Soros moves on

NPS (NPSP) rode a rollercoaster last week, falling $1.45 (26%) on a slew of news. The company stumbled out of the gates on Monday,

Read the full 273 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE